Cargando…
Gadoxetic acid-based hepatobiliary MRI in hepatocellular carcinoma
BACKGROUND & AIMS: SORAMIC is a prospective phase II randomised controlled trial in hepatocellular carcinoma (HCC). It consists of 3 parts: a diagnostic study and 2 therapeutic studies with either curative ablation or palliative Yttrium-90 radioembolisation combined with sorafenib. We report the...
Autores principales: | Ricke, Jens, Steffen, Ingo G., Bargellini, Irene, Berg, Thomas, Bilbao Jaureguizar, José Ignacio, Gebauer, Bernhard, Iezzi, Roberto, Loewe, Christian, Karçaaltincaba, Musturay, Pech, Maciej, Sengel, Christian, van Delden, Otto, Vandecaveye, Vincent, Zech, Christoph J., Seidensticker, Max |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7578758/ https://www.ncbi.nlm.nih.gov/pubmed/33103093 http://dx.doi.org/10.1016/j.jhepr.2020.100173 |
Ejemplares similares
-
Gadoxetic Acid-Based MRI for Decision-Making in Hepatocellular Carcinoma Employing Perfusion Criteria Only—A Post Hoc Analysis from the SORAMIC Trial Diagnostic Cohort
por: Seidensticker, Max, et al.
Publicado: (2022) -
Correlation of liver enhancement in gadoxetic acid–enhanced MRI with liver functions: a multicenter-multivendor analysis of hepatocellular carcinoma patients from SORAMIC trial
por: Öcal, Osman, et al.
Publicado: (2021) -
Non-hypervascular hepatobiliary phase hypointense lesions detected in patients with hepatocellular carcinoma: a post hoc analysis of SORAMIC trial to identify risk factors for progression
por: Öcal, Osman, et al.
Publicado: (2022) -
Prognostic value of baseline imaging and clinical features in patients with advanced hepatocellular carcinoma
por: Öcal, Osman, et al.
Publicado: (2021) -
Extrahepatic Disease in Hepatocellular Carcinoma: Do We Always Need Whole-Body CT or Is Liver MRI Sufficient? A Subanalysis of the SORAMIC Trial
por: Geyer, Thomas, et al.
Publicado: (2022)